Safety Alerts
Update on impurities in metformin products
Audiences
Consumer
Healthcare professional
Industry member
Product type
Therapeutic Products
6 December 2019
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
HSA would like to update the public on our actions and investigations into the contamination of metformin products with a nitrosamine impurity, N-nitrosodimethylamine (NDMA). Metformin is an oral diabetes medicine that helps control blood sugar levels. Combined with diet and exercise, metformin improves blood sugar level control in adults with type 2 diabetes mellitus.
Table caption
Types of communication | Date of release | Title |
|---|---|---|
HSA Update 1 | 4 Dec 2019 |
Testing methods for NDMA in metformin products
This sections features test methods developed by the Health Sciences Authority for the identification and determination of a nitrosamine impurity, N-nitrosodimethylamine (NDMA) in metformin products.
The testing method below provide options and guidance for the industry to detect NDMA in metformin products. This method should be validated by users to ensure they are fit for their intended use.
Table caption